Neuraly announces dosing of first patient in Phase 2 clinical trial
Category: #healthcare  By Akshay Kedari  Date: 2020-03-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

Neuraly announces dosing of first patient in Phase 2 clinical trial

Neuraly has claimed that it has dosed the first patient of NLY01 in its Phase 2 study for Parkinson’s disease.

Nature Medicine claimed in its study that NLYO1 tends to bind upregulated GLP-1R and blocks microglia’s pathological activation in animal models of disease such as Parkinson’s. Moreover, the study is believed to have revealed that NLYO1 averted death of neuronal cell and safeguarded against the decline of motor function following the derailment of pro-inflammatory cytokine products and glial activation.

President and CEO of Neuraly Seulki Lee highlighted that the present therapies meant for Parkinson’s disease offer merely temporary symptomatic enhancement and do not derail or stop the disease’s continuous surge.

He went on to signify the relevance of the Phase 2 study which is a stepping stone in the advancement of NLYO1 which will be a highly anticipated therapy for patients of Parkinson’s disease.

NLYO1 was tolerated in the Phase 1 study as it provided therapeutic doses with almost relentless exposure with once-in-a-week dose. Besides, NLYO1’s half-life was said to be around 12 and a half days and provided monitored weekly, attained 3-fold higher levels vis-à-vis shorter-acting GLP-1R agonists that are confined by downsides.

It is believed that the Phase 2 clinical trial will enroll around 240 patients in North America, including the U.S. and Canada. For the uninitiated, the Phase 2 clinical trial is a randomized, multicenter, placebo-controlled and double-blind trial. The trial is expected to analyze the efficacy, tolerability and safety of NLYO1 in cases with early Parkinson’s disease.

Neuraly’s Chief Scientific Officer of Neuraly Viktor Roschke expressed his delight at starting the Phase 2 study and stressed that their endeavor towards the treatment of the Parkinson’s disease and pre-empt the dip in function which is observed with prevalent therapies.

Source credit:

https://pipelinereview.com/index.php/2020030373936/Proteins-and-Peptides/Neuraly-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-of-NLY01-for-Patients-with-Parkinsons-Disease.html

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

CoreMap Announces Completion of $10.5 Million Series A Financing
CoreMap Announces Completion of $10.5 Million Series A Financing
By Akshay Kedari

CoreMap announced that it has accomplished $10.5 million Series A financing which was led by Qure Ve...

Spain to conduct first trial of Johnson & Johnson’s COVID-19 vaccine
Spain to conduct first trial of Johnson & Johnson’s COVID-19 vaccine
By Akshay Kedari

According to reliable sources, Spain is planning to host the phase 2 clinical trials of the US-based...

Fulcrum Biometrics acquires DelaneyBiometrics, adds European footprint
Fulcrum Biometrics acquires DelaneyBiometrics, adds European footprint
By Akshay Kedari

Fulcrum Biometrics, Inc. has announced a strategic acquisition of Delaney Secure Ltd., a UK-based bi...